Physicians' Academy for Cardiovascular Education

Concomitant use of ARNI does not alter the efficacy of sGC stimulator in HFrEF

Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial

Literature - Senni M, Alemayehu WG, Sim D, et al. - Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2608.

Introduction and methods

Background

Heart failure is related to impaired production of nitric oxide (NO) and decreased activity of its receptor, namely soluble guanylate cyclase (sGC). Deficiency of sGC-derived cyclic guanosine monophosphate (cGMP) contributes to myocardial and vascular dysfunction. Vericiguat is an sGC stimulator and restores cGMP deficiency through direct stimulation of sGC, independent of and synergistic with NO [1]. The placebo-controlled VICTORIA trial showed that vericiguat reduces the risk of cardiovascular death or first hospitalization for HF in patients with HFrEF [2]. However, the efficacy and safety of vericiguat in patients who received versus those who did not receive sacubitril/valsartan at randomization are unknown, as are the implications of follow-up (drop-in) use of sacubitril/valsartan.

Aim of the study

This secondary analysis of the VICTORIA trial compared the efficacy and safety of vericiguat between patients with HFrEF who were and were not treated concomitantly with sacubitril/valsartan.

Methods

The researchers used data from the VICTORIA trial, in which 5050 patients with HFrEF were randomized to treatment with vericiguat or placebo. They compared the efficacy and safety of vericiguat between patients with HFrEF who were and were not treated concomitantly with sacubitril/valsartan. The efficacy analyses first included only data from 677 patients who had been treated concomitantly with sacubitril/valsartan for at least 3 months from the time of randomization. Subsequently, analyses were performed based on data from 992 patients who had been treated concomitantly with sacubitril/valsartan for at least 3 months from the time of randomization or subsequently during follow-up (drop-ins). For the purpose of safety reporting, 164 patients who had been exposed to sacubitril/valsartan for less than 3 months were also considered.

Outcomes

The primary efficacy outcome was a composite of time to cardiovascular mortality or first hospitalization for HF. The secondary outcomes were the separate components of the composite primary outcome, time to total mortality or first hospitalization for HF, and time to total mortality. The safety outcomes were specific (serious) adverse events, namely symptomatic hypotension, syncope, worsening renal function (defined as increase in serum creatinine concentration ≥0.5 mg/dL or decrease in eGFR ≥25%, or both), and hyperkalemia (defined as increase in serum potassium concentration ≥1.0 mEq/L or serum potassium concentration >5.5 mmol/L).

Main results

General

Efficacy

Safety

Conclusion

This secondary analysis of the placebo-controlled VICTORIA trial shows that concomitant use of sacubitril/valsartan for at least 3 months does not alter the efficacy of vericiguat in patients with HFrEF. It is noteworthy that sacubitril/valsartan was started more frequently during the follow-up period in patients in the placebo group compared to those on vericiguat.

Concomitant sacubitril/valsartan therapy was similarly safe in both treatment groups, however a higher incidence of hypotension and syncope was observed in the vericiguat group compared to the placebo group among patients who started sacubitril/valsartan after randomization. The authors therefore suggest that caution is warranted in introducing sacubitril/valsartan in patients already on vericiguat.

References

Show references

Find this article online at Eur J Heart Fail.

Share this page with your colleagues and friends: